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Abstract
Lysosomal acid lipase (LAL) deficiency is an under-
recognized lysosomal disease caused by deficient 
enzymatic activity of LAL. In this report we describe 
two affected female Mexican siblings with early hepatic 
complications. At two months of age, the first sibling 
presented with alternating episodes of diarrhea and 
constipation, and later with hepatomegaly, elevated 
transaminases, high levels of total and low-density 
lipoprotein cholesterol, and low levels of high-
density lipoprotein. Portal hypertension and grade 2 
esophageal varices were detected at four years of 
age. The second sibling presented with hepatomegaly, 
elevated transaminases and mildly elevated low-
density lipoprotein and low high-density lipoprotein 
at six months of age. LAL activity was deficient in 
both patients. Sequencing of LIPA  revealed two 
previously unreported heterozygous mutations in exon 
4: c.253C>A and c.294C>G. These cases highlight 
the clinical continuum between the so-called Wolman 
disease and cholesteryl ester storage disease, and 
underscore that LAL deficiency represents a single 
disease with a degree of clinical heterogeneity.
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Core tip: Lysosomal acid lipase deficiency is a 
rare genetic disorder related to the metabolism of 
cholesterol and triglycerides inside the lysosome. In 
this report, we present the findings from two siblings 
with no lysosomal acid lipase activity caused by two 
previously unidentified mutations in exon 4 of LIPA . 
dyslipidemia and associated cardiac complications have 
also been reported[1,3]. The principal causes of  death 
reported in CESD patients were liver failure and bleeding 
of  esophageal varices[3]. However, bleeding of  esophageal 
varices was reported in only 8% of  patients[3], and this 
complication is primarily described in Mexican patients[5]. 
In this report, we describe the cases of  two Mexican 
siblings with LALD that was attributed to previously 
undescribed mutations in exon 4 of  LIPA. These siblings 
presented symptoms within the first year of  life and 
developed portal hypertension before four years of  
age. Both cases demonstrated early clinical signs and 
symptoms and relatively rapid clinical progression of  the 
disease compared to previously reported cases.
CASE REPORT
Sibling 1
This report describes the case of  a 9-year-old girl with 
healthy, non-consanguineous parents from Mexico, 
who was apparently normal at birth and met normal 
development milestones. She became symptomatic at two 
months of  age, presenting with alternating episodes of  
diarrhea and constipation, and reduced weight and height. 
Hepatomegaly was detected by abdominal radiography 
at six months of  age during the evaluation for diarrhea. 
An initial laboratory workup indicated leukocytosis 
(16000/mL) and eosinophilia (2700/mL), and a 
bone marrow analysis showed an increase of  myeloid 
series, with augmented cellularity and the presence of  
megakaryocytes, without immature cells. The patient then 
underwent additional testing to rule out a hematologic 
malignancy. Further workup included karyotype in 
peripheral blood, reported as 46, XX[20].
Laboratory assessments at two years of  age showed: 
hemoglobin, 14.1 g/dL; leukocytes, 13200/mL; 
eosinophilia, 3200/mL (24.6% of  white blood cell 
differential count); platelets, 330000; abnormal liver 
enzymes and dyslipidemia (Table 1) with evidence 
of  chronic Epstein-Barr virus infection. Serology for 
hepatitis A, B and C was negative. Hepatosplenomegaly 
was confirmed by abdominal ultrasound.
A computed tomography scan at four years of  age 
revealed an enlarged liver, with a longitudinal diameter 
of  18 cm and spleen length of  13.4 cm, without adrenal 
calcifications. The patient was transferred to the pediatric 
gastroenterology department in our hospital for further 
investigation for metabolic disease. She presented 
gastrointestinal bleeding and endoscopy revealed grade 2 
(Sohendra) esophageal varices.
When the patient was five years of  age, a hepatic 
biopsy showed multinodular microvesicular steatosis 
in 10% of  hepatocytes, with irregular small nodules 
separated by gross bands of  porto-portal fibrosis with 
no zonal preference, ballooning degeneration and 
pseudoacinar regeneration, and no stasis of  bilirubin or 
deposition of  copper or iron (Figure 1A, B). The portal 
triads were expanded by fibrous tissue, with sparse duct 
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The patients had early hepatic presentation, including 
severe cirrhosis and esophageal varices in the elder 
sibling, underscoring the significant morbidity that can 
occur at all ages of lysosomal acid lipase deficiency and 
highlighting possible compensatory mechanisms in liver 
function in children.
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INTRODUCTION
Lysosomal acid lipase deficiency (LALD; OMIM 
#278000) is an autosomal recessive disease caused by 
mutations in LIPA at chromosomal locus 10q23.31, 
which encodes a hydrolase involved in the degradation of  
lysosomal cholesterol esters and triglycerides. Clinically, 
LALD has been historically reported as one of  two 
principal phenotypic presentations: early onset, often 
called Wolman disease (WD), and late onset, termed 
cholesteryl ester storage disease (CESD)[1].
The early presentation of  LALD has an estimated 
prevalence of  1/350000 in infants, with symptoms such 
as diarrhea, massive hepatosplenomegaly, malabsorption, 
cachexia and adrenal calcifications, which typically develop 
within the first three months of  life. Liver cirrhosis 
results in fatal liver failure before one year of  age[1]. The 
exact prevalence of  LALD in children and adults is not 
yet established, and ranges from 1 in 150000 to 300000 
in Caucasians[1] and 1 in 40000 in German newborns[2]. 
The clinical signs and symptoms are heterogeneous, 
including hepatic steatosis leading to hepatomegaly and 
hepatic fibrosis and cirrhosis, splenomegaly, type Ⅱ 
hyperlipoproteinemia, and accelerated atherosclerosis. 
Although some patients remain asymptomatic until 
adulthood, infants and children can have significant 
morbidity and early mortality as a result of  liver cirrhosis 
and liver failure[3].
A review analyzing 135 CESD patients published in 
the literature found that the mean age at presentation was 
5 years (range: 1-44 years), with hepatomegaly as the most 
common manifestation[3]. In that review, Bernstein et al[3] 
noted that the age at presentation was between 0 and 2 
years in the most severely affected cases, corresponding 
to 27% of  patients and highlighting the significance of  
liver morbidity (cirrhosis, fibrosis, and failure). Another 
recent review showed that all 71 pediatric LALD cases 
had hepatomegaly, with 63% presenting symptoms 
before five years of  age[4]. The early signs of  portal 
hypertension and its correlation to hepatic fibrosis and 
the progression of  disease are unknown. Although 
liver manifestations of  the disease usually predominate, 
proliferation. Cells with foamy cytoplasm were observed 
in the portal space and in the fibrous tissue, which 
demonstrated diastase resistance and Periodic acid-Schiff  
positivity. Kupffer sinusoidal cells were immunopositive 
for CD68 (Figure 1C) and immunonegative for Hepar-1 
and pan-cytokeratin, with fine granules containing 
autofluorescent ceroid-like material (Figure 1D).
Doppler ultrasound at six years of  age showed a 
homogenous parenchyma, with normal echogenicity and 
without intrahepatic lesions or increased flux in portal 
circulation.
A duodenal biopsy performed when the patient was 
seven years of  age showed preserved architecture of  
duodenal mucosa, but with groups of  histiocytes with 
fluorescent ceroid material occupying about 40% of  the 
lamina propria of  villi (Figure 1E) that were associated 
with lymphocytes. A liver biopsy also demonstrated the 
same changes, with minimal steatosis that was decreased 
from the biopsy performed at five years. The histology 
indicated micronodular cirrhosis, widened portal spaces 
and fibrotic tissue with histiocytes, with an absence of  a 
central vein and nodules of  hepatic regeneration.
The pathologic findings of  the biopsies were 
interpreted as a possible diagnosis of  Niemann-Pick 
disease. Thus, sphingomyelinase activity was measured 
by mass spectrometry, and quantified as 2.3 µmol/L per 
hour (reference value ≥ 2 µmol/L per hour). A skin 
biopsy was taken to determine cholesterol esterification 
and filipin staining in cultured fibroblasts to eliminate 
Niemann-Pick type C disease (performed at Mayo 
Clinic, United States), revealing low-density lipoprotein 
esterification that was 2% of  normal control cells, similar 
to patients with Niemann-Pick type C disease, but with 
normal filipin staining.
The patient was not given any lipid-lowering drugs; 
recent laboratory test results are shown in Table 1. 
Associated with the progression of  her liver disease and 
the associated portal hypertension and splenomegaly, 
the patient’s platelet count decreased to 96000 (reference 
range: 150000-500000). Endoscopy performed at nine 
years of  age revealed continued presence of  grade 2 
esophageal varices (Figure 1F) and one medium gastric 
varix; the esophageal varices were ligated. The last 
Doppler ultrasound showed a longitudinal liver diameter 
of  14.7 cm, increased liver echogenicity, micronodular 
pattern, spleen longitudinal length of  14.6 cm, and 
increase in portal flux and collateral circulation with 
porto-systemic shunts (splenorenal shunt and umbilical 
vein recanalization) (Figure 2). The patient is currently 
being treated with propranolol (2 mg/kg per day) for 
gastrointestinal bleeding prophylaxis and vitamin K (10 
mg/d) for prolonged bleeding times.
Sibling 2
Given the suspicion of  a probable lysosomal storage 
disease in sibling 1, we began the study of  her now 
4-year-old sister at six months of  age. The initial physical 
examination revealed reduced height and hepatomegaly, 
which was confirmed by an abdominal ultrasound 
showing the liver with a longitudinal diameter of  8.4 
cm and increased echogenicity, and a spleen length of  
7.1 cm. Laboratory tests revealed alterations in liver 
function and lipid profile (Table 1); however, a bone 
marrow aspirate indicated no evidence of  storage disease. 
Sphingomyelinase activity was 2.8 µmol/L per hour. 
A recent endoscopy showed no varices, but Doppler 
ultrasound demonstrated increased hepatic flux, without 
porto-systemic shunts (Figure 2).
LAL enzymatic and molecular analyses
Following exclusion of  Niemann-Pick diseases, a 
diagnosis of  LALD was considered for both siblings. 
LAL activity was determined using a fluorescence-
based whole blood assay with 4-methylumbelliferone[6], 
which revealed < 0.02 pmol/punch*h (normal range: 
24.00-134.00 pmol/punch*h) in dried blood and 
0.000 nmol/punch*h in whole blood (normal range: 
0.027-0.152 nmol/punch*h). LAL activity from dried 
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Table 1  Hepatic function test, lipid profile and coagulation values in patients
Parameter (unit) Sibling 1 Sibling 2 Reference value
2 yr 9 yr 6 mo 4 yr
AST (U/L) 229 192   61 221 8-50
ALT (U/L) 344 193   56 181 7-45
Alkaline phosphatase (U/L) 365 545 328 402    4 yr: 169-372
   9 yr: 212-468
Lactate dehydrogenase (U/L) 258 281 288 236 4-6 yr: 145-345
7-9 yr: 143-290
Total bilirubin (mg/dL)        0.8          0.42        0.2          0.42 0.1-0.9
Indirect bilirubin (mg/dL)        0.7        0.2        0.1          0.28
Total cholesterol (mg/dL)    343.0    211.0    165.0    221.0   < 170
Triglycerides (mg/dL)    316.0    118.0    154.0    181.0 < 90
LDL-cholesterol (mg/dL)    277.1    157.4    123.0    154.8 < 100 (optimal)
HDL-cholesterol (mg/dL)      22.3      30.0      30.0      30.0 ≥ 60
Trombin time (min)        21.87      23.1      21.1      20.8 15-22
Prothrombin time (min)      13.9      14.8      12.0      12.4 11-15
pTT (min)      30.2      35.1      27.8      32.0 25-33
INR (%) 1.15 (92.8%) 1.3 (58.4%) 1 (100.8%) 1.1 (72.8%) 0.8-1.1 (89%-129%)
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that the father was a carrier of  the c.294C>G mutation, 
and the mother carried the c.253C>A mutation. This 
confirmed the trans-state of  mutations in the siblings.
Bioinformatics analyses using the Polyphen-2 and 
Sorting Intolerant From Tolerant (SIFT) predictive 
tools indicated that the exon 4 mutations are likely to 
be pathogenic, which was also indirectly demonstrated 
by the undetectable level of  LAL activity in whole 
blood and the very low incorporation of  low-density 
lipoprotein cholesterol in fibroblasts. These mutations 
were not found in other patients with LALD studied at 
the Massachusetts General Hospital, in the 1092 control 
individuals of  diverse ethnic background studied in the 
1000 Genomes Project (http://www.1000genomes.
org), or in the 6500 samples from NHLBI GO Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS), 
blood samples was 40.06 pmol/punch*h in the father, 
and 19.53 pmol/punch*h (low normal) in the mother.
LIPA sequencing
Genomic DNA was extracted from dried blood spots, 
and exons 1-10 of  LIPA were amplified by polymerase 
chain reaction and labeled with Big Dye Terminator 
(Applied Biosystems of  Thermo Fisher Scientific 
Inc., Waltham, MA, United States) and resolved by 
capillary electrophoresis on a 3730XL Genetic Analyzer 
(Applied Biosystems). Sequencing revealed a previously 
reported single nucleotide polymorphism within intron 
5 (rs2297472; c.539-5C>T), along with two previously 
unreported missense mutations in exon 4: c.253C>A 
(p.Gln85Lys) and c.294C>G (p.Asn98Lys) (Figure 3). 
Subsequent sequencing of  exon 4 in the parents showed 
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Figure 1  Liver histopathology and endoscopy images from sibling 1. A: Presence of ballooning and pseudoacinar regeneration, with foamy cells (HE, 
magnification × 400); B: Presence of portal triads expanded by fibrosis tissue and foamy cells (Masson’s tricromic, magnification × 400); C: Positive CD68 
immunoreactivity in cells (CD68 immunostaining); D: Autofluorescence of foamy cells in portal spaces (Masson’s tricromic, magnification × 400); E: Duodenal biopsy 
shows histiocytes with ceroid material in the lamina propria of the villi; F: Endoscopy showing esophageal varices.
A B
C D
E F
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Figure 2  Comparison of Doppler ultrasound images from sibling 1 (A,C) and sibling 2 (B,D). A: Splenic vein with a spontaneous splenorenal shunt; B: Splenic 
vein with collateral vessels at the hilum, without porto-systemic shunts; C: Dilated and tortuous vessels, collateral circulation and a spontaneous splenorenal shunt; D: 
Absence of a splenorenal shunt.
Heterozygous exon 4 c.253C>A (p.Gln85Lys)
130 140 150
Heterozygous exon 4 c.294C>G (p.Asn98Lys)
180 190
Figure 3  Electropherograms showing the mutations in exon 4 of the LIPA gene. A: Mutation in exon 4: c.253C>A (p.Gln85Lys); B: Mutation in exon 4: c.294C>G 
(p.Asn98Lys).
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suggesting that they are very rare.
DISCUSSION
There are several previous reports of  severe LALD in 
patients of  Mexican origin. A Mexican family was studied 
at Baylor College of  Medicine in Texas with three affected 
members who developed esophageal varices, hepatic 
failure and pulmonary complications early in life[7-10]. 
Another Mexican female studied at the same institute 
represented the first case of  hepatic transplantation 
in CESD after developing several complications[11]. In 
Mexico, two infants were diagnosed with Wolman disease 
by the characteristic adrenal calcification at autopsy[12,13], 
and another case was diagnosed by the presence 
of  crystal structures upon electron microscopy[14]. 
Considering the severity of  hepatic failure, it was thought 
that Mexican patients had more severe alleles or genes 
that modulated CESD[5]. Only two reports included a 
molecular diagnosis: a male infant affected by LALD 
(Mexican father and American mother) had Trp95X/
fs219 mutations[15]; and a female infant with a sibling that 
died at three months had compound heterozygosity for 
one new mutation: p.Gln98His/p.Gly342Arg[16].
The mutations found at amino acids 85 and 98 in 
exon 4 reported here are novel and were associated 
with undetectable whole blood enzyme activity, though 
a different mutation has been reported at amino acid 
85 (p.Gln85Arg)[3,17]. Although structural features of  
the LAL protein are not well defined, exon 4 may be 
functionally important as the majority of  mutations are 
within this exon[3,17] and its deletion causes LALD[3]. The 
absence of  detectable activity is an interesting finding 
because these siblings had early non-fatal complications, 
suggesting that LALD is a continuous phenotype with 
some cases presenting overlapping features of  Wolman 
disease and CESD, and indicating that enzymatic 
activity cannot predict the phenotype[3]. Studies of  the 
natural history of  LALD and correlating genotype and 
phenotype are urgently needed.
An exon 8 splice junction mutation (E8SJM) is 
present in the majority of  LALD cases[1]. A review of  the 
55 published cases of  LALD with molecular analysis of  
LIPA demonstrated that 89% of  patients had the E8SJM 
mutation in at least one allele[3]. Ethnicity influences 
the prevalence of  LALD, as a recent screen showed an 
increased frequency of  E8SJM carriers in Caucasian 
and Hispanic populations (1:300) compared to African 
American, Asian and Ashkenazi groups[18]. The cases 
reported here demonstrate that despite a high prevalence 
of  the E8SJM allele, LALD can originate from alternate 
mutations. In the Human Mutation Database, there are 
only 48 LIPA mutations reported to date in infant (19 
mutations) and child/adult (27 mutations) cases[17]. Thus, 
further studies of  carrier frequency of  mutations in the 
full LIPA gene are required.
Clinicians, particularly pediatric gastroenterologists/
hepatologists, should be aware of  LALD in view of  
the frequent reported pediatric presentations[3] and the 
potential for misdiagnosis. Children can have all the 
complications related to the progression of  cirrhosis, such 
as portal hypertension, ascites, esophageal/gastric varices, 
coagulopathy and bleeding; but these complications may 
not follow the adult pattern. Therefore, the detection of  
fibrosis, which progresses to cirrhosis, is a priority for the 
assessment of  hepatic dysfunction, the need for hepatic 
transplantation and prognosis. Hepatic biopsy is still the 
most reliable assessment of  progressive liver disease, 
so it is necessary to develop and validate noninvasive 
techniques that correlate with histopathology in order to 
identify fibrosis and to evaluate response to treatment, 
such as the recently developed dry blood spot assay for 
diagnostic confirmation of  LALD[6]. It is also necessary 
to explore the use of  Doppler ultrasound for identifying 
subtle changes in portal flow, and the presence of  
compensatory changes like recanalization of  umbilical 
vein and splenic renal shunts. Magnetic resonance 
spectroscopy can be used to quantify intrahepatic fat in 
LALD[19], but cannot evaluate the presence of  fibrosis.
The progression to fibrosis in sibling 1 corresponded 
with an increase in alanine aminotransferase levels, 
altering the ratio with aspartate aminotransferase. The 
patient also presented with a porto-systemic shunt (Figure 
2) that likely maintained stable portal hypertension 
and decreased the risk of  variceal bleeding, despite the 
extensive fibrosis. It is not clear if  these changes are the 
natural course of  hepatic compromise in pediatric LALD 
patients. Other cases of  LALD in Mexican patients 
demonstrate a rapid progression to hepatic failure[7-10].
Treatment for LALD has been limited to the use of  
lipid-lowering drugs or hepatic transplantation, which 
was performed in nine patients with mixed-results but 
with no long-term follow-up[3]. Sebelipase alfa (Synageva 
BioPharma Corp., Lexington, MA, United States), a 
recombinant human LAL, is under development for use 
as an enzymatic replacement therapy. The initial trial 
in adults showed a decrease in serum lipids and liver 
volume and normalization of  liver transaminases[20,21], 
and a phase 3 global trial is currently underway[22]. Timely 
diagnosis, as well as incorporation of  LAL activity in 
newborn screening, will be needed to optimize the 
time to begin enzymatic replacement therapy. Further 
research is needed for evaluating additional therapies 
for CESD patients, such as bone marrow and hepatic 
transplantation.
CONCLUSION
LALD is an underdiagnosed pediatric disease requiring 
an increased awareness and early diagnosis, particularly 
in Caucasian and Hispanic individuals. This report 
presents the cases of  two siblings carrying two previously 
unreported mutations in exon 4 of  LIPA that likely 
resulted in a deficiency of  LAL activity with early 
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symptomatology and complications.
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COMMENTS
Case characteristics
Two siblings were affected by lysosomal acid lipase deficiency with early 
manifestations and hepatic complications, with the elder presenting with 
bleeding episodes, esophageal varices and portal hypertension.
Clinical diagnosis
The two cases presented similar characteristics: sibling 1 presented with 
gastrointestinal manifestations (alternating diarrhea and constipation episodes), 
hepatomegaly, reduced height and weight; sibling 2 presented with reduced 
height and hepatomegaly on physical examination.
Differential diagnosis
Other lysosomal storage diseases with hepatomegaly and Niemann-Pick cells, 
such as acid sphingomyelinase-deficiency (Niemann-Pick B), Niemann-Pick C, 
and Tangier disease.
Laboratory diagnosis
High levels of total cholesterol, low-density lipoprotein, aspartate and alanine 
aminotransferases, and low levels of high-density lipoprotein, normal bilirubin 
and undetectable lysosomal acid lipase activity in blood.
Imaging diagnosis
For both cases, abdominal ultrasound showed hepatomegaly and Doppler 
ultrasound showed abnormal portal flux velocities. Endoscopy in sibling 1 
revealed esophageal varices.
Pathological diagnosis
In sibling 1, liver biopsy at five years of age showed microvesicular steatosis, 
foamy cells, fibrosis and cirrhosis.
Treatment
Both siblings were treated with a beta-blocker. Endoscopic variceal ligation was 
performed in sibling 1.
Related reports
Only one case of a Mexican infant with lysosomal acid lipase deficiency 
included LIPA mutation analysis. Other reports demonstrate that patients with 
the late presentation of this condition show severe hepatic disease with rapid 
progression.
Term explanation
Trans-state of mutations refers to mutations present in different alleles inherited 
from each parent.
Experiences and lessons
Limitations with enzymatic and molecular diagnosis along with a poor 
awareness of rare diseases can lead to a wrong diagnosis, as demonstrated in 
the patients reported here. New biochemical genetics techniques are available 
to achieve a correct diagnosis.
Peer review
The authors highlight the presentation of lysosomal acid lipase deficiency with 
hepatic complications and the importance of newly identified gene mutations. 
They also noted that enzyme levels were very low in the mother, a carrier of the 
mutation, suggesting that function is also impacted in a heterozygous state.
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